- Home
- ACP vs RIGL Comparison
ACP vs RIGL Comparison
Compare ACP & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACP | RIGL |
|---|---|---|
| Founded | 2010 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 663.7M | 564.7M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | ACP | RIGL |
|---|---|---|
| Price | $5.10 | $36.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $45.67 |
| AVG Volume (30 Days) | ★ 457.9K | 353.9K |
| Earning Date | 01-01-0001 | 05-05-2026 |
| Dividend Yield | ★ 17.79% | N/A |
| EPS Growth | N/A | ★ 1867.68 |
| EPS | N/A | ★ 0.44 |
| Revenue | N/A | ★ $294,282,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.75 |
| P/E Ratio | ★ N/A | $83.68 |
| Revenue Growth | N/A | ★ 64.15 |
| 52 Week Low | $4.99 | $19.51 |
| 52 Week High | $5.99 | $52.24 |
Technical Indicators
Market Signals| Indicator | ACP | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 38.11 | 42.92 |
| Support Level | $4.99 | $33.39 |
| Resistance Level | $5.48 | $36.95 |
| Average True Range (ATR) | 0.06 | 1.88 |
| MACD | -0.01 | -0.91 |
| Stochastic Oscillator | 7.55 | 18.52 |
Price Performance
Historical ComparisonAbout ACP abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income with a secondary objective of capital appreciation. It predominantly invests in debt and loan instruments of issues that operate in a variety of industries and geographic regions.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.